KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
A Rizzo, A Cusmai, S Acquafredda, F Giovannelli… - Future …, 2022 - Taylor & Francis
Stage I–III triple-negative breast cancer accounts for approximately 15–20% of new
diagnoses of early breast cancer. Novel systemic treatment options have recently been …
diagnoses of early breast cancer. Novel systemic treatment options have recently been …
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer.
A Rizzo, A Cusmai, S Acquafredda… - Future Oncology …, 2022 - europepmc.org
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new
diagnoses of early breast cancer. Novel systemic treatment options have recently been …
diagnoses of early breast cancer. Novel systemic treatment options have recently been …
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer
A Rizzo, A Cusmai, S Acquafredda… - Future oncology …, 2022 - pubmed.ncbi.nlm.nih.gov
Stage I-III triple-negative breast cancer accounts for approximately 15-20% of new
diagnoses of early breast cancer. Novel systemic treatment options have recently been …
diagnoses of early breast cancer. Novel systemic treatment options have recently been …